AbCellera Biologics (NASDAQ:ABCL - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.04), FiscalAI reports. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. The firm had revenue of $4.05 million for the quarter, compared to analyst estimates of $7.85 million.
AbCellera Biologics Stock Performance
Shares of ABCL traded down $0.17 during mid-day trading on Wednesday, hitting $5.92. 4,429,288 shares of the company's stock were exchanged, compared to its average volume of 5,700,607. The stock's 50-day moving average is $6.18 and its 200-day moving average is $4.64. AbCellera Biologics has a fifty-two week low of $2.74 and a fifty-two week high of $8.44. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -12.33 and a beta of 1.20.
Hedge Funds Weigh In On AbCellera Biologics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of AbCellera Biologics during the fourth quarter worth $26,938,000. Goldman Sachs Group Inc. grew its stake in AbCellera Biologics by 1,636.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company's stock worth $14,858,000 after purchasing an additional 4,094,268 shares in the last quarter. Bank of America Corp DE increased its holdings in AbCellera Biologics by 977.8% during the 3rd quarter. Bank of America Corp DE now owns 2,418,304 shares of the company's stock worth $12,164,000 after purchasing an additional 2,193,939 shares during the period. Tudor Investment Corp ET AL increased its holdings in AbCellera Biologics by 146.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 1,796,010 shares of the company's stock worth $6,142,000 after purchasing an additional 1,065,888 shares during the period. Finally, Two Sigma Investments LP raised its position in AbCellera Biologics by 25.9% in the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company's stock valued at $26,031,000 after purchasing an additional 1,064,290 shares in the last quarter. Hedge funds and other institutional investors own 61.42% of the company's stock.
Analyst Upgrades and Downgrades
ABCL has been the subject of a number of recent analyst reports. Benchmark upgraded shares of AbCellera Biologics from a "hold" rating to a "buy" rating and set a $11.00 price target for the company in a report on Tuesday, July 7th. Wall Street Zen cut AbCellera Biologics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of AbCellera Biologics in a research report on Friday, July 17th. JonesTrading initiated coverage on shares of AbCellera Biologics in a report on Friday, April 10th. They issued a "buy" rating and a $11.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of AbCellera Biologics in a research report on Tuesday, May 5th. They issued an "overweight" rating and a $7.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.
Read Our Latest Report on AbCellera Biologics
About AbCellera Biologics
(
Get Free Report)
AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.
AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
